Cochrane · systematic review · CD006745
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
Weis, S, Franke, A, Berg, T, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 1 · 14.3%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Percutaneous ethanol injection (PEI) or percutaneous acetic acid injection (PAI) for early hepatocellular carcinoma (HCC)
Population: hospitalised people with early HCC treated with PEI, PAI, or surgery.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PEI versus PAI | no estimate extracted | NR | No studies |
Overall survival | no estimate extracted | 185 participants | Low Downgraded: risk of bias |
Recurrence‐free survival | no estimate extracted | 185 participants | Low Downgraded: risk of bias |
Number and type of adverse events | no estimate extracted | NR | No studies |
Duration of hospital stay | no estimate extracted | 125 participants | Very low |
Quality of life | no estimate extracted | NR | No studies |
PEI versus surgery | no estimate extracted | NR | No studies |